Biochemical Assessment of Pheochromocytoma and Paraganglioma
Endocrine Reviews · 15.09.2023 · 44 (5) · 862-909
DOI: 10.1210/endrev/bnad011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Reviews, online erschienen am 30.03.2023. Verfasst von Graeme Eisenhofer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany. Hauptthemen laut MEDLINE: Pheochromocytoma, Paraganglioma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 116-mal zitiert (Crossref) und nennt 448 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Pheochromocytoma and paraganglioma (PPGL) require prompt consideration and efficient diagnosis and treatment to minimize associated morbidity and mortality. Once considered, appropriate biochemical testing is key to diagnosis. Advances in understanding catecholamine metabolism have clarified why measurements of the O-methylated catecholamine metabolites rather than the catecholamines themselves are important for effective diagnosis. These metabolites, normetanephrine and metanephrine, produced respectively from norepinephrine and epinephrine, can be measured in plasma or urine, with choice according to available methods or presentation of patients. For patients with signs and symptoms of catecholamine excess, either test will invariably establish the diagnosis, whereas the plasma test provides higher sensitivity than urinary metanephrines for patients screened due to an incidentaloma or genetic predisposition, particularly for small tumors or in patients with an asymptomatic presentation. Additional measurements of plasma methoxytyramine can be important for some tumors, such as paragangliomas, and for surveillance of patients at risk of metastatic disease. Avoidance of false-positive test results is best achieved by plasma measurements with appropriate reference intervals and preanalytical precautions, including sampling blood in the fully supine position. Follow-up of positive results, including optimization of preanalytics for repeat tests or whether to proceed directly to anatomic imaging or confirmatory clonidine tests, depends on the test results, which can also suggest likely size, adrenal vs extra-adrenal location, underlying biology, or even metastatic involvement of a suspected tumor. Modern biochemical testing now makes diagnosis of PPGL relatively simple. Integration of artificial intelligence into the process should make it possible to fine-tune these advances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
- Department of Internal Medicine, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands.
ORCID-Profile: Graeme Eisenhofer, Christina Pamporaki, Jacques W M Lenders
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Eisenhofer, G., Pamporaki, C., & Lenders, J. W. M. (2023). Biochemical Assessment of Pheochromocytoma and Paraganglioma. Endocrine Reviews, 44(5), 862-909. https://doi.org/10.1210/endrev/bnad011
Vancouver
Eisenhofer G, Pamporaki C, Lenders JWM. Biochemical Assessment of Pheochromocytoma and Paraganglioma. Endocrine Reviews. 2023;44(5):862-909. doi:10.1210/endrev/bnad011
BibTeX
@article{Eisenhofer2023,
author = {Eisenhofer, Graeme and Pamporaki, Christina and Lenders, Jacques W M},
title = {Biochemical Assessment of Pheochromocytoma and Paraganglioma},
journal = {Endocrine Reviews},
year = {2023},
volume = {44},
number = {5},
pages = {862--909},
doi = {10.1210/endrev/bnad011}
}
EUVIMED